SeQure dx, is applying state of the art genomics technologies for CRISPR gene editor target profiling to advance discovery, clinical development, and diagnostic solutions. Their technologies provide the foundation needed to ensure that life-saving gene therapies will be both safe and effective.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/03/21 | $17,500,000 | Series A |
Alexandria Venture Investments Bold Capital Casdin Capital Digitalis Ventures KdT Ventures Mass General Brigham Ventures  RiverVest Venture Partners | undisclosed |
